Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR-mutated NSCLC
The results from the Phase 3 MARIPOSA study were announced showing amivantamab-vmjw in combination with…
Browsing: ESMO
ESMO 2023: Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR-mutated NSCLC
The results from the Phase 3 MARIPOSA-2 study have been announced showing the regimen of…
ESMO 2O23: Major pathologic response to neoadjuvant pembrolizumab in advanced melanoma trial exceeds 50 percent
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III-IV…
ESMO 2023: Highlights on pembro + CRT in high-risk locally advanced cervical cancer: The KEYNOTE-A18 study
ESMO 2023: Highlights on belzutifan in previously treated advanced clear cell RCC: The LITESPARK-005 study
ESMO 2023: Highlights on sotorasib plus panitumumab in KRAS G12C-mutated mCRC: The CodeBreak 300 study
ESMO 2023: Lung cancer treatment research enters a new era
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs…
ESMO 2023: Advances in gynaecological cancer research could change the treatment landscape
Results from highly anticipated phase 3 clinical trials in gynaecological cancers with, among others, new…
ESMO 2023: Dual-action drug produces positive results in patients with advanced neuroendocrine tumours, trial finds
A drug that simultaneously strikes cancer cells’ growth circuits and pipeline to the bloodstream produced…